| Filed On | Filing |
|---|---|
| 13 Oct 2026 |
Form 3: Kalter Sandra C, Director
No securities owned |
| 21 Sep 2026 |
Form 4: Smith Trent N., CFO
Received 15,000 shares as a grant or award |
| 16 Sep 2026 | FORM 424B3 |
| 16 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Appointment adds more than four decades of MedTech leadership, FDA regulatory and strategic transaction experience, including work supporting renal denervation and other category-defining technologies |
| 15 Sep 2026 | EFFECT |
| 14 Sep 2026 | FORM DEFA14A |
| 14 Sep 2026 | Proxy statement: annual meeting on October 29, 2026 |
| 11 Sep 2026 | FORM 424B5 |
| 08 Sep 2026 |
Form 4: Klemp Walter V, Director
Received 13,000 shares as a grant or award |
| 08 Sep 2026 |
Form 4: Bisson Lori, Director
Received 13,000 shares as a grant or award |
| 08 Sep 2026 |
Form 4: Hauser Bradley, CEO and President
Received 27,000 shares as a grant or award |
| 04 Sep 2026 | FORM PRE 14A |
| 04 Sep 2026 | FORM S-3 |
| 26 Aug 2026 | 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more |
| 13 Aug 2026 | FORM 10-Q |
| 04 Aug 2026 | EFFECT |
| 31 Jul 2026 | FORM 424B5 |
| 28 Jul 2026 | FORM S-3 |
| 28 Jul 2026 | 8-K: Other Events |
| 15 Jul 2026 | 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more |
Loading...
